Medtronic Transcatheter Aortic Valve Replacement in Low Risk Patients

What is the purpose of this trial?

The study objective is to demonstrate that the safety and effectiveness of the Medtronic TAVR system as measured by rates of all-cause mortality or disabling stroke at two years is noninferior to SAVR in the treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR.


Participation Guidelines

Ages: 18 years and older

Gender: Both


Medtronic, Inc

Dates: 07/29/2016 - 12/31/2016

Last Updated: 07/30/2016

Study HIC#: 1603017500

Get Involved

For more information about this study, contact:
Linda T Levesque
203-737-6483
linda.levesque@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

John Kiene Forrest

Principal Investigator

Sub-Investigators